ABEONA THERAPEUTICS INC. (ABEO): M&A transaction — Abeona closes sale of Rare Pediatric Disease PRV for $155M; cash at $225M

ABEONA THERAPEUTICS INC.

Closed sale of Rare Pediatric Disease Priority Review Voucher for $155M gross proceeds on June 27, 2025.
Unrestricted cash, equivalents, and short-term investments totaled approximately $225M as of June 30, 2025.
CFO expects over two years of operating capital without further capital infusion; profitability projected early 2026.
First ZEVASKYN patient treatment anticipated in Q3 2025.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ABEONA THERAPEUTICS INC. completed a disposition involving buyer for gross proceeds of $155 million (closed 2025-06-27).

Action: disposition
Counterparty: buyer
Consideration: gross proceeds of $155 million
Closing: 2025-06-27

Exact text from the filing

terms of an asset purchase agreement dated May 9, 2025 (the “PRV Asset Purchase Agreement”). Pursuant to the PRV Asset Purchase Agreement, the Company received gross proceeds of $155 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV Asset Purchase Agreement does not purport to be complete and is qualified in its entirety

View on SEC.gov

Browse all m&a transactions →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001641172-25-017460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.